2021 | Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials | Guttman-Yassky, Emma; Teixeira, Henrique D.; Simpson, Eric L.; Papp, Kim A.; Pangan, Aileen L.; Blauvelt, Andrew; Thaçi, Diamant; CHIA-YU CHU ; Hong, H. Chih ho; Katoh, Norito; Paller, Amy S.; Calimlim, Brian; Gu, Yihua; Hu, Xiaofei; Liu, Meng; Yang, Yang; Liu, John; Tenorio, Allan R.; Chu, Alvina D.; Irvine, Alan D. | The Lancet | 264 | 220 | |
2023 | Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis | Silverberg, Jonathan I; Guttman-Yassky, Emma; Thaçi, Diamant; Irvine, Alan D; Stein Gold, Linda; Blauvelt, Andrew; Simpson, Eric L; CHIA-YU CHU ; et al., | The New England journal of medicine | 49 | 22 | |